Precision tremor measurement for ET clinical trials
Digital kinematic endpoints for essential tremor clinical trials extract continuous tremor frequency, amplitude, and velocity from a brief drawing assessment. NeuroQuantix complements the established TETRAS clinical scale (which provides regulatory precedent and clinical interpretability) with the high-frequency objective measurement that increases sensitivity to treatment effects in ET, a condition affecting an estimated 7 million people in the US.
Published effect sizes on digitized spiral analysis enable smaller, faster trials with objective, regulatory-grade endpoints. NeuroQuantix standardizes this evidence into a pre-specified endpoint for your program. Learn more about essential tremor from the NINDS/NIH overview.
Limitations of TETRAS
The The Essential Tremor Rating Assessment Scale (TETRAS) is the current gold standard for essential tremor assessment in clinical trials. These are its documented limitations. See the FDA guidance for essential tremor for regulatory context.
The ET Measurement Challenge
Essential tremor trials have long relied on TETRAS and FTM clinician-rated scales. These scales provide established regulatory precedent and clinical interpretability — they are valuable. The opportunity is to add continuous, objective kinematic measurement alongside them, capturing the frequency-amplitude-velocity relationships that define tremor pathophysiology and improving the trial's sensitivity to treatment effects. For novel therapeutics targeting specific tremor frequencies (such as T-type calcium channel modulators or Cav3 inhibitors), pairing scales with digital endpoints provides the precision needed to detect the treatment effect.
Clinical Applications
Published Evidence
Evidence from peer-reviewed publications supporting digital kinematic endpoints for essential tremor assessment. View the full evidence base.
Velocity Spectral Peak
A sensitive single metric for ET tremor quantification — captures tremor frequency and amplitude in a single continuous measure with strong test-retest reliability.
Haubenberger D, et al. Movement Disorders, 2011Frequency-Amplitude Decomposition
Spectral analysis of pen velocity separates tremor components by frequency, enabling discrimination of ET from enhanced physiological tremor.
Haubenberger D, et al. Movement Disorders, 2011Pharmacological Sensitivity
Published data demonstrates that digitized tremor metrics detect propranolol response with substantial sensitivity for treatment-effect monitoring.
Published literature consensus
Statistical Power Advantage
Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on the NeuroQuantix platform page.
View Power VisualizationFrequently Asked Questions
What digital endpoints exist for essential tremor clinical trials?
NeuroQuantix provides digital kinematic endpoints for essential tremor clinical trials based on digitized spiral analysis. The platform extracts tremor frequency, amplitude, velocity, and spectral characteristics from a brief drawing assessment at 240 samples per second. The result is continuous, objective measurement that complements traditional clinician-rated scales like TETRAS in modern trial designs.
How does NeuroQuantix work alongside TETRAS in ET clinical trials?
TETRAS provides decades of regulatory precedent and clinical interpretability for essential tremor trials. NeuroQuantix complements TETRAS by adding continuous, high-frequency kinematic measurement that captures tremor frequency, amplitude, and velocity directly. Many modern ET trial designs use both — TETRAS as the regulatorily-precedented endpoint and digital kinematic endpoints to improve sensitivity and increase the probability of detecting real treatment effects.
How can sample size be reduced in essential tremor clinical trials?
Continuous, high-frequency kinematic measurement provides substantially higher sensitivity than ordinal scales, which translates to greater statistical power per subject. The result is powered studies with smaller cohorts at equivalent statistical power. For gene therapy and rare-disease ET programs, this measurement-precision lever can determine whether a powered study is feasible at all.
How does NeuroQuantix provide objective essential tremor assessment?
NeuroQuantix captures tremor frequency, amplitude, and velocity from a brief drawing assessment with high-frequency continuous measurement. Spectral analysis decomposes tremor across frequency bands relevant for ET, enabling frequency-specific treatment effect detection. Each metric is preserved separately rather than compressed into a composite score, allowing detection of domain-specific treatment effects that complement the global picture provided by traditional clinical scales.
Explore Further
23 Conditions
Full differential with evidence tiers and gene therapy applications.
NeuroQuantix Platform
Regulatory-grade digital endpoints backed by published effect sizes.
Published Research
Scoping review of 120 studies in Movement Disorders Clinical Practice.
Endpoint Consulting
Strategic endpoint selection for your essential tremor program.
Parkinson's Disease
Digital kinematic endpoints for parkinson's disease clinical trials.
Ready to discuss essential tremor endpoints?
Schedule a consultation to explore how precision digital endpoints can strengthen your essential tremor clinical program.